iScience (Mar 2024)

Placental efflux transporters and antiseizure or antidepressant medication use impact birth weight in MoBa cohort

  • Marta H. Hernandez,
  • Jacqueline M. Cohen,
  • Karoline H. Skåra,
  • Thea K. Grindstad,
  • Yunsung Lee,
  • Per Magnus,
  • Pål R. Njølstad,
  • Ole A. Andreassen,
  • Elizabeth C. Corfield,
  • Alexandra Havdahl,
  • Espen Molden,
  • Kari Furu,
  • Maria C. Magnus,
  • Alvaro Hernaez

Journal volume & issue
Vol. 27, no. 3
p. 109285

Abstract

Read online

Summary: Low birth weight raises neonatal risks and lifelong health issues and is linked to maternal medication use during pregnancy. We examined data from the Norwegian Mother, Father, and Child Cohort Study and the Medical Birth Registry of Norway, including 69,828 offspring with genotype data and 81,189 with maternal genotype data. We identified genetic risk variants in placental efflux transporters, calculated genetic scores based on alleles related to transporter activity, and assessed their interaction with prenatal use of antiseizure or antidepressant medication on offspring birth weight. Our study uncovered possible genetic variants in both offspring (rs3740066) and mothers (rs10248420; rs2235015) in placental efflux transporters (MRP2-ABCC2 and MDR1-ABCB1) that modulated the association between prenatal exposure to antiseizure medication and low birth weight in the offspring. Antidepressant exposure was associated with low birth weight, but there were no gene-drug interactions. The interplay between MRP2-ABCC2 and MDR1-ABCB1 variants and antiseizure medication may impact neonatal birth weight.

Keywords